Acellular antibordetella vaccine
AssigneeInstitut Pasteur
InventorsPascale Gueirard, Nicole Guiso
Life of this patent
Estimating the term…
Abstract
The invention relates to an immunogenic composition, characterized in that it comprises an adenyl cyclase-hemolysin (AC-Hly) protein, or an immunogenic portion of this AC-Hly, of a strain of Bordetella chosen from B. pertussis, B. parapertussis or B bronchiseptica, and in that it comprises, in addition, a bacterial extract containing the expression products of the vrg genes of a strain of Bordetella chosen from B. pertussis, B. parapertussis or B bronchiseptica, or a portion of these expression products which is sufficient to induce an immune response in a host to which the extract might be administered.
Claims43
An immunogenic composition comprising
- (a) an adenyl cyclase-hemolysin (AC-Hly) toxin, or an immunogenic portion of AC-Hly of a strain of Bordetella selected from the group consisting of B. pertussis, B. parapertussis, and B bronchiseptica, and
- (b) a bacterial extract containing the expression products of the vrg genes of a strain of Bordetella selected from the group consisting of B. pertussis, B. parapertussis, and B bronchiseptica, or a portion of these expression products, sufficient to induce an immune response in a host to which the extract is administered.
A vaccinating composition, comprising
- (a) an adenyl cyclase-hemolysin (AC-Hly) protein or an immunogenic portion of AC-Hly of a strain of Bordetella selected from the group consisting of B. pertussis, B. parapertussis, and B. bronchiseptica;
- (b) a bacterial extract containing the expression products of the vrg genes of a strain of Bordetella selected from the group consisting of B. pertussis, B. parapertussis, and B. bronchiseptica, or a portion of these expression products, sufficient to induce an immune response in a host to which the extract is administered;
- (c) optionally, one or more adhesins or toxins of Bordetella selected from the group consisting of B. pertussis, B. parapertussis, and B bronchiseptica, wherein the adhesin or toxin is selected from the group consisting of FHA, the AGGs, PRN, and PTX;
- and
- (d) a pharmaceutically acceptable vehicle and, where appropriate, an adjuvant.
An immunogenic composition comprising
- (a) an adenyl cyclase-hemolysin (AC-Hly) protein, or an immunogenic portion of AC-Hly of a strain of Bordetella selected from the group consisting of B. pertussis, B. parapertussis, and B bronchiseptica,
- (b) a B. pertussis, B. parapertussis, or B. bronchiseptica strain whose bvgS gene is mutated such that the bacterium expresses the vrg genes but not the vag genes, and
- (c) optionally, one or more adhesins or toxins of Bordetella selected from the group consisting of B. pertussis, B. parapertussis, and B. bronchiseptica, wherein the adhesin or toxin is selected from the group consisting of FHA, the AGGs, PRN, and PTX.
A vaccinating composition comprising
- (a) an adenyl cyclase-hemolysin (AC-Hly) protein, or an immunogenic portion of AC-Hly of a strain of Bordetella selected from the group consisting of B. pertussis, B. Paraiyertussis, and B. bronchiseptica,
- (b) a B. pertussis, B. parapertussis or B. bronchiseptica strain whose bvgS gene is mutated such that the bacterium expresses the vrg genes but not vag genes,
- (c) optionally one or more adhesins or toxins of Bordetella selected from the group consisting of B. pertussis, B. parapertussis, and B. bronchiseptica, wherein the adhesin or toxin is selected from the group consisting of FHA, the AGGs, PRN, and PTX, and
- (d) a pharmaceutically acceptable vehicle and, where appropriate, an adjuvant.
Dependencies are inferred from the claim text.